NCT05905484

Study of Bemnifosbuvir on Cardiac Repolarization in Healthy Subjects

A Phase 1, Double-blind, Single-dose, Randomized, Placebo and Active-Controlled, Four-Way Crossover Study Evaluating the Effects of Bemnifosbuvir on Cardiac Repolarization in Healthy Adult Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 35 (actual)
• Sponsor: Atea Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This study will assess the effects of Bemnifosbuvir on cardiac repolarization in healthy Adult Subjects

Conditions

• Healthy Volunteer Study

Interventions

Type	Name	Description
DRUG	Bemnifosbuvir (BEM)	A single dose of BEM will be administered.
DRUG	Placebo	A single dose of matching placebo will be administered.
DRUG	Moxifloxacin	A single dose of Moxifloxacin will be administered.

Timeline

• Start date: 2023-04-25
• Primary completion: 2023-05-31
• Completion: 2023-05-31
• First posted: 2023-06-15
• Last updated: 2023-06-15

Locations

1 site across 1 country: Canada

Regulatory

• FDA-regulated drug study